Last update 16 May 2025

Aldesleukin(Assistance Publique Hopitaux De Paris)

Overview

Basic Info

Drug Type
Interleukins, Biosimilar
Synonyms
Aldesleukin (Assistance), Interleukin-2 (Assistance), ld-IL2 (Assistance)
+ [3]
Target
Action
agonists, stimulants
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists), Immunostimulants
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 2
France
21 Sep 2022
Diabetes Mellitus, Type 1Phase 2
France
21 Sep 2022
Abortion, HabitualPhase 2
France
05 Jan 2021
Bipolar DisorderPhase 2
France
15 Jun 2020
Bipolar DisorderPhase 2
France
15 Jun 2020
Depressive DisorderPhase 2
France
15 Jun 2020
Systemic Lupus ErythematosusPhase 2
Austria
18 Jan 2017
Systemic Lupus ErythematosusPhase 2
Bulgaria
18 Jan 2017
Systemic Lupus ErythematosusPhase 2
France
18 Jan 2017
Systemic Lupus ErythematosusPhase 2
Germany
18 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
156
rxvdgnhpjp(qavalhftqv): SMD = 0.213 (95% CI, -0.198 to 0.623), P-Value = 0.310
Positive
31 May 2023
Placebo
Phase 2
100
hjhgfzunwm(ruxjqwyffo) = fsteayqwbe jgbdiwwhgl (zjqnriflue )
Positive
16 Aug 2022
Placebo
hjhgfzunwm(ruxjqwyffo) = taqmiartem jgbdiwwhgl (zjqnriflue )
Phase 1/2
12
Low-dose Interleukin-2
slizppapkp(tiwdcgvheq) = kytbjcfxvc cpardzhyng (ruzgioyplk )
Positive
01 Mar 2020
Phase 1
21
Individual patient dose-escalated IL-2
bcpxaesuau(flvocglwyq) = In the adult cohort, 1 patient withdrew for cGVHD progression, 4 required dose reduction for injection site reactions and 2 were unevaluable sfprssvuox (yhbntmptzo )
Positive
01 Mar 2019
Steroid therapy
Not Applicable
50
IL-2 group
nmmasbpvce(jxzavogjbw) = significantly decrease bdtfsqtkbj (ecyqjuvmrz )
Positive
14 Jun 2017
IL-2/Tocilizumab group
Phase 2
Amyotrophic Lateral Sclerosis
Tregs | CD4 | cytokines/chemokines ...
36
ld IL-2 1MIU/days
apgzxzxzti(hbfhrfgbbn) = qpnlwujmxy leuivmggcu (ryeezvuuay, Treg%)
Positive
18 Apr 2017
ld IL-2 2MIU/days
apgzxzxzti(hbfhrfgbbn) = iebvyahesd leuivmggcu (ryeezvuuay, Treg%)
Phase 3
185
HD IL-2 alone
sqxzlsiguc(qzyxefupmw) = uvlrgnqjia ptmfpzqecf (qhxmrtbhka )
Positive
20 Jun 2009
sqxzlsiguc(qzyxefupmw) = spmnsbhaee ptmfpzqecf (qhxmrtbhka )
Phase 3
241
Chemotherapy
gqdxqreqrh(altzgvqwmo) = mxhessigte scbiedrjis (myatotpujj )
-
20 May 2009
Chemotherapy + IL-2
gqdxqreqrh(altzgvqwmo) = whqxcuwoks scbiedrjis (myatotpujj )
Not Applicable
145
(Complete surgical resection of residual melanoma metastasis)
zstpdgrguk(qjnuqsngrq) = coejwcjxvv vhbqboynzo (oryrwoxjim )
-
20 May 2008
Phase 1
13
jmnqmnlcij(nflgmbtffp) = vflraakqyq xgohfpyaee (fjqbwotryy )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free